Connect your AI

CytomX Therapeutics CTMX Shares (Basic)

Shares (Basic) at other companies

PfizerPFE

5.7B+0.3%

AmgenAMGN

540M+0.4%

Janux TherapeuticsJANX

62.7M+1.4%

Allogene TherapeuticsALLO

240.3M+11.6%

Vor BiopharmaVOR

43M+589%

Design Therapeutics, Inc.DSGN

61.4M+8.2%

Other financials

Income statement

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CytomX Therapeutics's shares (basic)?: CytomX Therapeutics (CTMX) reported shares (basic) of 177.3M in Q1 2026.
How has CytomX Therapeutics's shares (basic) changed year-over-year?: CytomX Therapeutics's shares (basic) increased by 103.5% year-over-year, from 87.1M to 177.3M.
What is the long-term trend for CytomX Therapeutics's shares (basic)?: Over 4 years (2021 to 2025), CytomX Therapeutics's shares (basic) has grown at a 19.3% compound annual growth rate (CAGR), from 256.5M to 519.1M.
What does shares (basic) mean?: The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.